activity
20242026
collaborators
Showing stat.MEShow all

5 papers · 1 filter

stat.ME2026

Communicating results in trials with multiple hypotheses or adaptive design features

Elina Asikanius, Marcel Wolbers, Mouna Akacha +8

Over time, clinical trials have increasingly incorporated complex design and analysis elements such as interim analyses, adaptations, multiple endpoints, and sophisticated multipli…

stat.ME2025

Exhausting the type I error level in event-driven group-sequential designs with a closed testing procedure for progression-free and overall survival

Moritz Fabian Danzer, Kaspar Rufibach, Jan Beyersmann +1

In oncological clinical trials, overall survival (OS) is the gold-standard endpoint, but long follow-up and treatment switching can delay or dilute detectable effects. Progression-…

stat.ME2025

"6 choose 4": A framework to understand and facilitate discussion of strategies for overall survival safety monitoring

Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2

Advances in anticancer therapies have significantly contributed to declining death rates in certain disease and clinical settings. However, they have also made it difficult to powe…

stat.ME2025

Balancing events, not patients, maximizes power of the logrank test: and other insights on unequal randomization in survival trials

Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2

We revisit the question of what randomization ratio (RR) maximizes power of the logrank test in event-driven survival trials under proportional hazards (PH). By comparing three app…

stat.ME2024

Using shrinkage methods to estimate treatment effects in overlapping subgroups in randomized clinical trials with a time-to-event endpoint

Marcel Wolbers, Mar Vázquez Rabuñal, Ke Li +2

In randomized controlled trials, forest plots are frequently used to investigate the homogeneity of treatment effect estimates in subgroups. However, the interpretation of subgroup…